X0609 4/A 2026-06-26 2026-06-30 0001815442 Kymera Therapeutics, Inc. KYMR 0001451612 Booth Bruce false C/O KYMERA THERAPEUTICS, INC. 500 NORTH BEACON STREET, FLOOR 4 WATERTOWN MA 02472 true false false false 1 Common Stock 2026-06-29 4 S 0 5549 105.78 D 2446375 I See footnote Common Stock 2026-06-29 4 S 0 14798 106.63 D 2431577 I See footnote Common Stock 2026-06-29 4 S 0 19419 107.76 D 2412158 I See footnote Common Stock 2026-06-29 4 S 0 10848 108.28 D 2401310 I See footnote Common Stock 2026-06-29 4 S 0 7968 109.75 D 2393342 I See footnote Common Stock 2026-06-29 4 S 0 7723 110.67 D 2385619 I See footnote Common Stock 2026-06-29 4 S 0 934 111.20 D 2384685 I See footnote Common Stock 2026-06-29 4 S 0 770 105.78 D 471497 I See footnote Common Stock 2026-06-29 4 S 0 2133 106.63 D 469364 I See footnote Common Stock 2026-06-29 4 S 0 2698 107.76 D 466666 I See footnote Common Stock 2026-06-29 4 S 0 1498 108.28 D 465168 I See footnote Common Stock 2026-06-29 4 S 0 1104 109.75 D 464064 I See footnote Common Stock 2026-06-29 4 S 0 1078 110.67 D 462986 I See footnote Common Stock 2026-06-29 4 S 0 130 111.20 D 462856 I See footnote This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.015 to $106.0145 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (3) and (5) through (10). These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.0271 to $106.96 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.03 to $108.0293 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.0326 to $109.019 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.034 to $109.96 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.09 to $111.08 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.09 to $111.63 inclusive. The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any. This Amendment is being filed to address an inadvertent clerical error in the original Form 4 relating to the allocation of the reported sales between Atlas Venture Fund X and AVOF. The aggregate number of shares sold by Atlas Venture Fund X and AVOF, as reported in the original Form 4, remains unchanged. /s/ Ommer Chohan, Attorney-in-Fact 2026-07-02